IPP Bureau
Torrent Pharma reports Q4 FY25 PAT at Rs. 498 Cr
By IPP Bureau - May 26, 2025
The revenue witnessed a growth of 7.80 per cent on a year-on-year basis at Rs. 2,959 crore
Gland Pharma Q4 FY25 PAT falls to Rs. 186.5 Cr
By IPP Bureau - May 26, 2025
R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4?revenue
Divi's Laboratories inks manufacturing and supply agreement with global pharma company
By IPP Bureau - May 26, 2025
The company expects meaningful revenue contribution from this long-term agreement
Lupin and SteinCares ink agreement for Ranibizumab in Latin America
By IPP Bureau - May 26, 2025
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Glenmark Pharma reports Q4 FY25 PAT at Rs. 346.6 Cr
By IPP Bureau - May 24, 2025
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
Sun Pharma to raise stake in US-based Pharmazz to 22.7%
By IPP Bureau - May 24, 2025
Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%
CPHI & PMEC China sees surge in international attendance
By IPP Bureau - May 24, 2025
Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth
Strides Pharma Q4 net profit rises 5x to Rs. 113 Cr
By IPP Bureau - May 24, 2025
For the full year FY25, net profit soared 12x to Rs 345 crore
Indoco Remedies receives final approval from the USFDA for Allopurinol Tablets USP
By IPP Bureau - May 24, 2025
Allopurinol is used to prevent or lower high uric acid levels in the blood
Alembic Pharmaceuticals announces USFDA final approval for Amlodipine and Atorvastatin Tablets USP
By IPP Bureau - May 24, 2025
Amlodipine and Atorvastatin tablets are indicated in patients for whom treatment with both amlodipine and atorvastatin
Shilpa Medicare partners with Orion for Recombinant Human Albumin for European market
By IPP Bureau - May 24, 2025
Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe
Zydus receives final approval from USFDA for Isotretinoin Capsules USP
By IPP Bureau - May 24, 2025
Isotretinoin capsules are indicated to treat severe, disfiguring nodular acne
Biocon gets six-month extension on insulin supply pact in Malaysia
By IPP Bureau - May 23, 2025
The company was awarded the insulins supply contract for a three-year period in 2022 through April 2025
Astellas and Pfizer’s XTANDI shows overall survival in metastatic hormone-sensitive prostate cancer
By IPP Bureau - May 23, 2025
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30%
Merck KGaA, Darmstadt, Germany, Showcases Innovation at ASCO 2025
By IPP Bureau - May 23, 2025
Merck KGaA, Darmstadt, Germany announced the presentation of new oncology data across more than 12 tumor types at ASCO 2025
